S. Kerridge

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine

Caitlin E. Mullarkey, Ly-Mee Yu, A. Pollard, 2012, The Pediatric infectious disease journal.

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine

A. Pollard, M. Sadarangani, Ushma Galal, 2020, Molecular systems biology.

Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers

A. Pollard, B. Angus, M. Voysey, 2015, BMJ Open.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.

S. Faust, A. Pollard, C. Oeser, 2011, Vaccine.

A Cross-Sectional Observational Study of Pneumococcal Carriage in Children, Their Parents, and Older Adults Following the Introduction of the 7-Valent Pneumococcal Conjugate Vaccine

Shannon N. Fenlon, D. Crook, J. Hinds, 2015, Medicine.

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial

Ly-Mee Yu, A. Pollard, B. Angus, 2017, The Lancet.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

A. Pollard, P. Aley, L. Godfrey, 2022, The Lancet.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.

S. Madhi, K. Dheda, P. Aley, 2020 .

Epidemiological studies of large resistance plasmids in Haemophilus.

T. Peto, D. Crook, O. Secka, 2000, The Journal of antimicrobial chemotherapy.

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

A. Pollard, Ushma Galal, M. Snape, 2020, Open forum infectious diseases.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution

J. Farrar, G. Dougan, K. Holt, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model

S. Baker, M. Levine, A. Pollard, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

D. Bonsall, V. Libri, J. Vekemans, 2021 .

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

P. Klenerman, A. Winston, G. Screaton, 2021, The Lancet HIV.

Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

S. Hoffman, R. Longley, A. Lawrie, 2013, PloS one.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal

D. Murdoch, D. Kelly, A. Pollard, 2021, The Journal of infectious diseases.

Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.

D. Murdoch, J. Hinds, D. Kelly, 2015, The Lancet. Infectious diseases.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

G. Screaton, P. Aley, B. Angus, 2021, SSRN Electronic Journal.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

A. Pollard, P. Aley, M. Voysey, 2023, Clinical and experimental immunology.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.

A. Pollard, C. Oeser, N. Andrews, 2011, Health technology assessment.

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

S. Faust, A. Pollard, C. Oeser, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.